6. - 12. August 2005 in Sydney, Australien
Pressemitteilung | |
|---|---|
Erfolg versprechende Phase II-Ergebnisse für Wirksamkeit und Sicherheit von BAY 59-7939 vorgestellt - Start der Phase III des klinischen Entwicklungsprogramms in diesem Jahr |
|
Hintergrundinformationen | |
|---|---|
(nur in Englisch verfügbar) Thromboembolic disorders: A major cause of morbidity and mortality |
|
Current anticoagulant therapies |
|
Coagulation Pathway |
|
Glossar |
|
An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – For Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: A Dose-ranging Study
Prevention Of Venous Thromboembolism With An Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – In Elective Hip Replacement: A Dose-Ranging Study
Aspirin Has No Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor
Interaction Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – With Antiplatelet Agents: Monitoring And Therapeutic Applications
Effect Of BAY 59-7939 – A Novel, Oral, Direct Factor Xa Inhibitor – on Clot-Bound Factor Xa Activity In Vitro
Effect of Enoxaparin on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 – an Oral, Direct, Factor Xa Inhibitor
The Oral, Direct Factor Xa Inhibitor – BAY 59-7939 – Inhibits Thrombin Generation In Vitro After Tissue Factor Pathway Activation
Antithrombotic Mechanism of Action of BAY 59-7939 – a Novel, Oral, Direct Factor Xa Inhibitor
Comparison of the Anticoagulant Properties of BAY 59-7939 – an Oral, Direct Factor Xa Inhibitor – with Fondaparinux and Enoxaparin
ISTH Homepage: www.isth.org
Sie verlassen die Website der Bayer AG.
Die Bayer AG ist für den Inhalt der nachfolgenden Website nicht verantwortlich.
sammeln